The next generation RNA therapeutics market presents significant growth opportunities, driven by the development of over 100 RNA therapies and vaccines, advancing research, and robust investment ...

A Ghanaian Scientist’s breakthrough research on fluorescent molecular probes could transform how the world detects cancer at ...

Codexis, Inc. (NASDAQ:CDXS) Q4 2025 Earnings Call Transcript March 11, 2026 Codexis, Inc. beats earnings expectations. Reported EPS is $0.1056, expectations were $-0.03. Operator: Greetings. Welcome ...

Earnings call Codexis reported Q4 2025 revenue of $38.9M (up 81% YoY), with full-year revenue rising 19% to $70.4M. Product gross margin improved to 64% (from 56% prior year). 2026 revenue is guided ...

Annovis Provides Corporate Updates And Reports Fiscal Year 2025 Financial Results. MALVERN, Pa., March 16, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the“Company”), a Phase ...

Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy ...

A metabolic enzyme studied for over seven decades has a hidden second function—it can unwind RNA and promote cell cycle progression, an additional function beyond its role in energy production, ...

Scientists at Georgetown University's Lombardi Comprehensive Cancer Center have uncovered a new dual function for a well-known cancer-related protein called ezrin. This finding could potentially open ...

Scientists at Georgetown University's Lombardi Comprehensive Cancer Center have uncovered a new dual function for a ...

This week saw both Regenxbio and Solid Bio report new data with their gene therapy candidates for Duchenne muscular dystrophy ...

Kerendia has hit the spot in another phase 3 trial that could extend its use as a treatment for patients with chronic kidney disease (CKD). Extending the label for Kerendia is a strategic priority for ...